<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58518">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668134</url>
  </required_header>
  <id_info>
    <org_study_id>09-1345 / 201107319</org_study_id>
    <nct_id>NCT01668134</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Feasibility Study of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if targeted radiation therapy (stereotactic) can be
      given to treat liver cancer, for patient who are unable to undergo surgery, over a short
      period of time with a small amount of side effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.</measure>
    <time_frame>Up to 90 days after end of radiation therapy</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the late toxicity associated with using stereotactic radiation therapy in patients with unresectable HCC and IHC.</measure>
    <time_frame>Up to 60 days after end of radiation therapy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the local recurrence rates associated with using SBRT in patients with unresectable HCC and IHC.</measure>
    <time_frame>Time of treatment until recurrance or progressive disease as measured by CT/MR from baseline to recurrance or progressive disease</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the overall survival rates associated with using SBRT in patients with unresectable HCC and IHC.</measure>
    <time_frame>Baseline to time of death</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the response rates associated with using SBRT in patients with resectable HCC and IHC</measure>
    <time_frame>Baseline  to the first date of recurrance or progressive disease</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Stereotactic  radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiation</intervention_name>
    <arm_group_label>Stereotactic  radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Karnofsky Performance Status of ≥ 60

          -  Pathologically confirmed IHC or HCC. (Pathology not required for HCC if the lesion
             enhances typically on MRI and the patient is evaluated by liver transplant surgery
             team and thought to have HCC.)

          -  4 or less separate intrahepatic lesions, with at least one lesion that is able to be
             followed by EASL Criteria.

          -  Local surgical resection is not possible due to tumor or patient factors

          -  Limited metastatic disease is allowed if the volume of metastatic disease does not
             exceed the volume of primary disease.

          -  Prior TACE allowed if stopped/completed at least 2 weeks prior to enrollment

          -  Prior chemotherapy except Sorafenib allowed if stopped/completed at least 2 weeks
             prior to enrollment

          -  Prior Sorafenib allowed if stopped/completed at least seven days prior to enrollment.

          -  Able to provide signed informed consent

        Exclusion Criteria:

          -  Childs-Pugh score 9 or more

          -  ALT or AST ≥ 6 x upper limit of normal

          -  Prior history of abdominal irradiation

          -  Women who are pregnant or nursing

          -  Scheduled to undergo chemotherapy except Sorafenib at the time when radiation therapy
             will be given, or for up to 4 weeks after completion of radiation therapy.

          -  Scheduled to undergo Sorafenib within seven days of when radiation therapy will be
             delivered, or for up to 2 weeks after completion of radiation therapy.

          -  Undergone prior radiation therapy to the abdomen.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Parikh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parag Parikh, M.D.</last_name>
    <phone>314-362-8525</phone>
    <email>pparikh@radonc.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina Smith</last_name>
    <phone>314-454-7986</phone>
    <email>smithr@wudosis.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Parikh, M.D.</last_name>
      <phone>314-362-8525</phone>
      <email>pparikh@radonc.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>William Chapman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Doyle, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Darcy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neal Saad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darryl Zuckerman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Korenblat, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Crippin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Lisker-Melman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Wang-Gillam, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Picus, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Sorscher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Fowler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd DeWees, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
